Inhibition of inflammatory mediators contributes to the anti-inflammatory activity of KYKZL-1 via MAPK and NF-κB pathway

Toxicology and Applied Pharmacology

Volumn 272, Issue 1, 2013, Pages 221-229

  Xu, Guang Lin ^a,d   Du, Yi Fang ^a   Cheng, Jing ^a   Huan, Lin ^a   Chen, Shi Cui ^b   Wei, Shao Hua ^a   Gong, Zhu Nan ^a   Cai, Jie ^a   Qiu, Ting ^a   Wu, Hao ^a   Sun, Ting ^a   Ao, Gui Zhen ^c  

^a NANJING NORMAL UNIVERSITY   (China)

^b Jinhu Food and Drug Administration   (China)

^c SOOCHOW UNIVERSITY   (China)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

COX; Inflammation; Inflammatory mediators; LOX; NSAIDs

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 2; DICLOFENAC; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KYKZL 1; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; OXYGENASE INHIBITOR; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; XYLENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATTENUATION; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; EAR EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMUNOMODULATION; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH LESION; STOMACH ULCER; WESTERN BLOTTING;

COX; INFLAMMATION; INFLAMMATORY MEDIATORS; LOX; NSAIDS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CELL LINE; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; EDEMA; INDICATORS AND REAGENTS; INFLAMMATION MEDIATORS; LEUKOTRIENE B4; LIPOPOLYSACCHARIDES; LIPOXYGENASE INHIBITORS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED ICR; NF-KAPPA B; NITRIC OXIDE; PHENYLPROPIONATES; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; STILBENES; STOMACH ULCER; XYLENES;

EID: 84882975242     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.05.025     Document Type: Article

References (28)

1. Anderson N., Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol. Rev. 2008, 60:311-357.
2. Bannwarth B. Is licofelone, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, a promising alternative in anti-inflammatory therapy?. Fundam. Clin. Pharmacol. 2003, 18:125-130.
3. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 2002, 196:254-265.
4. Brune K. Safety of anti-inflammatory treatment - new ways of thinking. Rheumatology 2004, 43(Suppl. 1):i16-i20.
5. Cario E., Rosenberg I.M., Brandwein S.L., Beck P.L., Reinecker H.C., Podolsky D.K. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J. Immunol. 2000, 164:966-972.
6. Celotti F., Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol. Res. 2001, 43:429-436.
7. Charlier C., Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem. 2003, 38:645-659.
8. Chung C.P., Avalos I., Raggi P., Stein C.M. Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin. Rheumatol. 2007, 26:1228-1233.
9. Coruzzi G., Venturi N., Spaggiari S. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond. Acta. Biomed. 2007, 78:96-110.
10. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
11. Du G.H., Li X.J., Zhang Y.X. Drug Discovery and Evaluation-Pharmacological Assays (Chinese version) 2001, 636. Science Press, China.
12. Fiorucci S., Meli R., Bucci M., Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?. Biochem. Pharmacol. 2001, 62:1433-1438.
13. Hoogstraate J., Andersson L.I., Berge O.G., Jonzon B., Ojteg G. COX-inhibiting nitric oxide donators (CINODs) - a new paradigm in the treatment of pain and inflammation. Inflammopharmacology 2003, 11:423-428.
14. Kleinert H., Pautz A., Linker K., Schwarz P.M. Regulation of the expression of inducible nitric oxide synthase. Eur. J. Pharmacol. 2004, 500:255-266.
15. Kneen, G., Jackson, W.P., Islip, P.J., Wates, P.J., 1986. Preparation of arylhydroxamic acid derivative 530 compositions containing them, and their use in medicine and other applications. 531 European Patent 196184.
16. Kopydlowski K.M., Salkowski C.A., Cody M.J., van Rooijen N., Major J. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J. Immunol. 1999, 163:1537-1544.
17. Martel-Pelletier J., Lajeunesse D., Reboul P., Pelletier J.P. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis. 2003, 62:501-509.
18. Oeckinghaus A., Ghosh S. The NF-κB family of transcription factors and its regulation. Cold Spring Harb. Perspect. Biol. 2009, 1:a000034.
19. Olajide O.A., Makinde J.M., Okpako D.T., Awe S.O. Studies on the anti-inflammatory and related pharmacological properties of the aqueous extract of Bridelia ferruginea stem bark. J. Ethnopharmacol. 2000, 71:153-160.
20. Palsson-McDermott E.M., O'Neill L.A. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 2004, 113:153-162.
21. Santucci L., Fiorucci S., Di Matteo F.M., Morelli A. Role of tumor necrosis factor-α release and leukocyte margination in indomethacin-induced gastric injury in rats. Gastroenterology 1995, 108:393-401.
22. Shankar S., Singh G., Srivastava R.K. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front. Biosci. 2007, 12:4839-4854.
23. Song H.Y., Lee J.A., Ju S.M., Yoo K.Y., Won M.H., Kwon H.J., Eum W.S., Jang S.H., Choi S.Y., Park J. Topical transduction of superoxide dismutase mediated by HIV-1 Tat protein transduction domain ameliorates 12-O- tetradecanoyl- phprbol-13-acetate (TPA)-induced inflammation in mice. Biochem. Pharmacol. 2008, 75:1346-1357.
24. Surh Y.J., Chun K.S., Cha H.H., Han S.S., Keum Y.S., Park K.K., Lee S.S. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat. Res. 2001, 480-481:243-268.
25. Tayeh M.A., Marletta M.A. Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. J. Biol. Chem. 1989, 264:19654-19658.
26. Wallace J.L., Del Soldato P. The therapeutic potential of NO-NSAIDs. Fund. Clin. Pharmacol. 2003, 17:11-20.
27. Wallace J.L., Caliendo G., Santagada V., Cirino G., Fiorucci S. Gastrointestinal safety and antiinflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 2007, 132:261-271.
28. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 2006, 12:1005-1015.